Polycythemia Vera clinical trials at UC Irvine
2 research studies open to eligible people
Showing trials for
Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera
open to eligible people ages 18-90
The main purpose of this study is to evaluate the efficacy of sapablursen in reducing the frequency of phlebotomy and in improving quality of life assessments in participants with polycythemia vera.
Orange, California and other locations
Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
open to eligible people ages 18 years and up
This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).
Irvine, California and other locations
Our lead scientists for Polycythemia Vera research studies include Angela G. Fleischman.
Last updated: